Shionogi

Brexit deal defeated again, crucial no-deal vote awaits

This appears to be having an impact on pharma investment in the UK, with Japanese company Shionogi announcing this week that it plans to relocate its European headquarters from London to

Shionogi planning HQ move from UK

Brexit understood to be main reason for switch. Japanese drugmaker Shionogi will transfer its European headquarters from the UK to the Netherlands as a consequence of the Brexit, according to the ... Shionogi isn’t commenting on the report, but the

Roche’s new flu pill Xofluza approved in US

Discovered and developed by Shionogi, the drug is already approved in Japan, with Roche holding the marketing rights outside Japan and Taiwan.

Encouraging data for Roche flu drug ahead of FDA decision

Discovered and developed by Shionogi, the drug is already approved in Japan and marketed as Xofluza, with Roche holding the marketing rights  outside Japan and Taiwan.

Roche’s Tamiflu successor hits the mark in complicated flu

Also in its favour is that baloxavir marboxil is already on the market in Japan, where its originator Shionogi won approval earlier this year as Xofluza.

[ Previous 5 results ] 2 3 4 5 6 7 8 9 10 11 [ Next 5 results ]